Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 5/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433175 | 0.94 | APLNR (0.50) | APLNROPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL31433179 | 0.92 | RAMP3 (0.49) | APLNROPRM1OPRK1 | |
| SCHEMBL31433264 | 0.91 | CXCR4 (0.58) | APLNR | |
| SCHEMBL31433441 | 0.91 | CXCR4 (0.58) | APLNR | |
| SCHEMBL31433189 | 0.90 | IL23R (0.53) | — | |
| SCHEMBL31433182 | 0.88 | APLNR (0.56) | APLNROPRM1NMUR2NMUR1OPRD1 | |
| SCHEMBL31433319 | 0.88 | IL23R (0.52) | — | |
| SCHEMBL31433237 | 0.88 | NMUR2 (0.61) | OPRM1OPRK1NMUR2NMUR1OPRD1 | |
| SCHEMBL31433350 | 0.88 | CXCR4 (0.57) | APLNR | |
| SCHEMBL31433213 | 0.87 | CXCR4 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | APLNR 2565/4885OPRM1 2906/4885OPRK1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.